Combining and Sequencing Agents with Immunotherapies in Prostate Cancer
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.
Clinical Pearls:
- Theoretically, many therapies with targets and toxicities that do not overlap could be used together, though this has not been studied
- Early phase II studies are being conducted looking at sipuleucel-T with or without enzalutamide or abiraterone, though they are not likely to be particularly informative as they are both tolerable therapies
- Trials are not yet being done to answer the question as to whether combining or sequencing agents and immunotherapies can actually improve outcomes
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
